Literature DB >> 29558660

The effect of dabigatran on thrombin generation and coagulation assays in rabbit and human plasma.

Chi Zhang1, Peizhe Zhang2, Hongxia Li1, Lianhua Han1, Lei Zhang3, Lei Zhang3, Xiangjun Yang4.   

Abstract

OBJECTIVES: Dabigatran etexilate is widely used for stroke prevention in the patients with atrial fibrillation. The anticoagulation activity of dabigatran is not necessary monitored in routine clinical practice. We aimed to study the effect of dabigatran on thrombin generation (TG) and coagulation assays in rabbit and human plasma.
METHODS: Rabbits received different concentrations of dabigatran etexilate (5 mg/kg, 10 mg/kg). Patients with atrial fibrillation took 110 mg dabigatran etexilate twice daily. The concentrations of dabigatran in rabbit and human plasma were detected by liquid chromatography/tandem mass spectrometry (LC-MS/MS) and ecarin chromogenic assay (ECA). The relationship between plasma dabigatran concentrations and the activated partial thromboplastin time (aPTT), prothrombin time (PT), thrombin time (TT), and TG were evaluated.
RESULTS: There was strong correlation between LC-MS/MS and ECA (P < 0.001). Bland Altman analysis demonstrated that ECA assay could accurately predict human plasma dabigatran concentrations whereas underestimate the plasma concentrations of dabigatran in rabbits. Both the PT and the aPTT assays showed low correlations with dabigatran. The TT assay was highly sensitive to dabigatran levels. Low concentrations of dabigatran paradoxically increased TG.
CONCLUSIONS: LC-MS/MS is the gold standard for detecting the concentrations of dabigatran. ECA correlates well with LC-MS/MS. The coagulation assays depend more on other factors. Paradoxical enhancement of TG may predict clinically rebound hypercoagulability and warrants further exploration.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Coagulation assays; Dabigatran; Ecarin clotting time; LC-MS/MS; Thrombin generation

Mesh:

Substances:

Year:  2018        PMID: 29558660     DOI: 10.1016/j.thromres.2018.03.012

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  5 in total

Review 1.  Perioperative management of patients with atrial fibrillation receiving anticoagulant therapy.

Authors:  Takeshi Omae; Keito Koh; Masateru Kumemura; Sonoko Sakuraba; Yosuke Katsuda
Journal:  J Anesth       Date:  2019-05-08       Impact factor: 2.078

2.  Interspecies comparison of simultaneous thrombin and plasmin generation.

Authors:  Ivan D Tarandovskiy; Hye Kyung H Shin; Jin Hyen Baek; Elena Karnaukhova; Paul W Buehler
Journal:  Sci Rep       Date:  2020-03-03       Impact factor: 4.379

3.  The Comparison of Therapeutic Efficacy Between Dabigatran Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation.

Authors:  Hongxia Li; Lei Zhang; Ming Xia; Chi Zhang; Tingbo Jiang
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

4.  Effects of direct oral anticoagulants dabigatran and rivaroxaban on the blood coagulation function in rabbits.

Authors:  Lu Yin; Yuan Qi; Zhiru Ge; Jiajin Li
Journal:  Open Life Sci       Date:  2022-01-28       Impact factor: 0.938

5.  The in vitro addition of idarucizumab to plasma samples from patients increases thrombin generation.

Authors:  Mojca Božič Mijovski; Rickard E Malmström; Nina Vene; Jovan P Antovic; Alenka Mavri
Journal:  Sci Rep       Date:  2021-03-15       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.